Biogen Stock Forecast, Price & News

Biogen's stock was trading at $294.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BIIB shares have decreased by 7.7% and is now trading at $271.67.
View which stocks have been most impacted by COVID-19.

33 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 5 sell ratings, 15 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Biogen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIIB, but not buy additional shares or sell existing shares.
View analyst ratings for Biogen or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Biogen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biogen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

186 employees have rated Biogen CEO Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among Biogen's employees.

Biogen is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Biogen.

Biogen will be holding an earnings conference call on Wednesday, February 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Biogen Inc. (NASDAQ:BIIB) posted its quarterly earnings results on Wednesday, October, 21st. The biotechnology company reported $8.84 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $8.06 by $0.78. The biotechnology company had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.34 billion. Biogen had a trailing twelve-month return on equity of 51.00% and a net margin of 35.63%. The firm's quarterly revenue was down 6.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $9.17 earnings per share.
View Biogen's earnings history.

Biogen announced that its board has approved a stock buyback plan on Monday, December 23rd 2019, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company's leadership believes its stock is undervalued.

33 analysts have issued twelve-month price objectives for Biogen's shares. Their forecasts range from $175.00 to $450.00. On average, they expect Biogen's stock price to reach $305.97 in the next twelve months. This suggests a possible upside of 12.6% from the stock's current price.
View analysts' price targets for Biogen or view Wall Street analyst' top-rated stocks.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN), Ionis Pharmaceuticals (IONS), Novavax (NVAX) and United Therapeutics (UTHR).
View all of BIIB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), The Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and The Boeing (BA).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.25%), New York State Teachers Retirement System (0.15%), DNB Asset Management AS (0.11%), Retirement Systems of Alabama (0.06%), Nisa Investment Advisors LLC (0.06%) and Strs Ohio (0.05%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin.
View institutional ownership trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including DNB Asset Management AS, KAMES CAPITAL plc, State of Alaska Department of Revenue, Hexavest Inc., Busey Wealth Management, New York State Teachers Retirement System, Pendal Group Limited, and Cullinan Associates Inc.. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, and Stephen A Sherwin.
View insider buying and selling activity for Biogen or view top insider-selling stocks.

BIIB stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Louisiana State Employees Retirement System, Rhenman & Partners Asset Management AB, Timber Creek Capital Management LLC, FNY Investment Advisers LLC, Retirement Systems of Alabama, Prairiewood Capital LLC, and Kestra Advisory Services LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos.
View insider buying and selling activity for Biogen or or view top insider-buying stocks.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $271.67.

Biogen has a market capitalization of $41.81 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

The official website for Biogen is www.biogen.com.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]